March 2025 |
What’s in a pronoun? Besides the obvious, Hims and Hers Health – a leading online/telehealth resource for any number of products and services – has gotten into something that may be of concern to you: they’ve acquired a NJ-based at-home laboratory testing facility and will now offer in-home blood draws and testing.
H&H's entry into the blood draw market, where they will compete with Labcorp and Quest Diagnostics, could potentially affect your laboratory. Tests include those for LDL cholesterol, lipoprotein(a), cholesterol, and apolipoprotein, may lead to a drop in tests performed at your laboratory due to the convenience of in-home testing.
A single-use lancet will put a small amount of blood from the upper arm into a microtube.
The impetus here is to ensure you’re paid the most you can be on your claims, especially if you notice a drop in tests due to in-home testing. You’ll need to do that for your patients - both the hims and hers - who depend on your laboratory!
(ADSRCM ensures that our laboratory clients’ claims are submitted for maximum reimbursement, and with a nearly 99% success rate on first-attempt clearinghouse submissions.)
Click here for the H&H press release.
The ADSRCM Laboratory Team looks forward to seeing you at the 2025 Executive War College conference in New Orleans next month! We hope you enjoy the rest of the read!
When patients or their authorized caregivers are blocked from access to their medical information, or they experience delays in that access, the offending party (e.g., the practice, the hospital, and yes, the laboratory) can be penalized by the 21st Century Cures Act.
It’s why EHRs, for example, should be ONC-certified, which means they’re Cures Act compliant and, therefore, aren’t blocking information as described.
Penalties are happening. For example, HHS recently levied a $200,000 civil fine against an OR-based healthcare entity for “violating an individual’s right to timely access to her medical records.”
The complaint was made to the Office of Civil Rights (OCR), which oversees these matters. It was the second complaint against this same entity. In short, the OCR determined that the healthcare entity “failed to take timely action in response to the right of access requests.” In December 2024, the entity received notification of the $200,000 fine.
The lesson is crystal clear: the Cures Act is not to be taken lightly. It must be respected, or serious penalties could be levied.
Proposed new centralization updates to their peer review process for “grants, cooperative agreements, and research and development contracts within the agency’s Center for Scientific Review (CSR)” have been made by the National Institutes of Health (NIH).
The centralization effort will apply to the first stage of the review process. NIH’s CSR ensures independent, expert reviews without inappropriate influence. CSR manages the peer review process for over 78% of NIH grants.
The MA Attorney General announced indictments against several MassHealth providers for urine tests and at-home services that weren’t provided, and/or were medical unnecessary, or/or weren’t properly authorized.
The entities involved (which includes two laboratories) and their owners, were allegedly involved in close to $8 million in fraudulent MassHealth claims to Medicare.
The allegations include how one of the players is a physician who authorized home health care services and laboratory tests even though that physician hadn’t seen those patients or provided any care to them, and that many of the patients involved were hospitalized or deceased during the time the supposed services were provided.
Click here for details from the MA Attorney General’s office.
United Healthcare (UHC) has a group plan called Surest. Perhaps unsurprisingly, it happens to be UHC’s best-selling plan. Surest features copays only with no deductibles, no coinsurance, and no cost shifting.
Health Care Service Corporation (HCSC) has its own version of this with their “Simplified Health Care Coverage Option.” If you’re not familiar with HCSC, under its auspices are Blue Cross Blue Shield of IL, MT,
NM, OK, and TX. Apparently, the “no deductibles/copays only” concept is catching on.
What do these insurance plans potentially mean for clinical laboratories and anatomic pathology groups? No doubt there’d be reduced patient A/R since responsibility balances for deductibles wouldn’t exist under those plans.
Click here for details from the HCSC press release
(Regardless of your patients’ insurance coverage, ADSRCM empowers you to capture responsibility balances to the best extent possible with access to our patient responsibility estimator, with out-of-network alerts, with an automated prior authorizations option, with our team performing eligibility verifications up to four times prior to tests, and with a balance due reminder texting option.)
In a whistleblowing case, the reportedly third largest laboratory in the US will pay over $700,000 to resolve allegations of billing the government for unnecessary blood testing. The relator (aka “whistleblower”) will receive nearly $113,000.
The allegation explains how the laboratory, from 2012 to 2023, conducted much more expensive blood testing than what medical providers prescribed for those patients. More specifically, CBC tests were typically ordered without WBC (white blood count). However, the laboratory performed those tests with WBC, making them more complex calling for larger reimbursements.
Click here for the Justice Department’s details.
You can drive maximized revenue and productivity for your laboratory with outsourced services from ADSRCM, or about the MedicsPremier platform from ADS if in-laboratory automation is preferred! Contact us at 844-599-6881 or email rcminfo@adsc.com for more information, and about the ADSRCM guarantee to increase your revenue in 90 days.
We strive to provide our newsletters with news of the current month, not the previous month. Feedback or comments on our newsletters/content are greatly appreciated. Please opine by emailing marc.klar@adsc.com or by calling me at 973-931-7516. We’d love to hear from you!
Marc E. Klar, Vice President, Marketing, ADSRCM.
Medical Billing / RCM | Laboratory
Laboratories that offer specialized services such as molecular testing and Next Generation ...
By Jim O'Neill
on December 4th, 2024
Industry News | Laboratory
The recent updates to the Clinical Laboratory Improvement Amendments (CLIA) by the Centers for ...
By Gene Spirito, MBA
on October 23rd, 2024
Medical Billing / RCM | Laboratory
Discover how an advanced laboratory billing system, including top-tier lab billing software and ...
By Stephen O'Connor
on December 13th, 2017
Disclaimer: Articles and content about governmental information, such as CMS, Medicare, and Medicaid, are presented according to our best understanding. Please visit www.cms.gov if clarifications are needed. We are not responsible for typographical errors or changes that may have occurred after this newsletter was produced. We don’t endorse any companies or organizations mentioned in our newsletters; you are encouraged to do research and due diligence on any that might interest you.